CIK 0001434647
- Non-accelerated filer
- Smaller reporting company
ZEVRA THERAPEUTICS, INC.
Sign in to watch- Ticker
- ZVRA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 205894398
- Phone
- +1 888-958-1253
- Business address
- 101 FEDERAL STREET, BOSTON, MA, 02110
- Former names
- KEMPHARM, INC, KEMPHARM INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $224,948
- in 1 filing, $225K under 10b5-1 plans
Net −$224,948. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2015-04-21 | Plooster Matthew R Director | Conversion · Series C Convertible Preferred Stock | −8,381 | 0 | ||
| 2015-04-21 | Plooster Matthew R Director | Conversion · Series A Convertible Preferred Stock | −1,701,011 | 0 | ||
| 2015-04-21 | Plooster Matthew R Director | Conversion · Series B Convertible Preferred Stock | −1,511,279 | 0 | ||
| 2015-04-21 | Plooster Matthew R Director | Conversion · Warrant to Purchase Series D Preferred Stock (right to buy) | −384 | $0.78 | $300 | 0 |
| 2015-04-21 | Plooster Matthew R Director | Conversion · Warrant to Purchase Common Stock (right to buy) | +51 | 51 | ||
| 2015-04-21 | Mickle Travis C President & CEO | Conversion | +5,983 | 277,094 | ||
| 2015-04-21 | Mickle Travis C President & CEO | Conversion | +96,288 | 96,288 | ||
| 2015-04-21 | Mickle Travis C President & CEO | Conversion · Series A Convertible Preferred Stock | −527,093 | 0 | ||
| 2015-04-21 | Mickle Travis C President & CEO | Conversion · Series B Convertible Preferred Stock | −6,203 | 0 | ||
| 2015-04-21 | Mickle Travis C President & CEO | Conversion · Series C Convertible Preferred Stock | −51,332 | 0 | ||
| 2015-04-21 | Mickle Travis C President & CEO | Conversion · Series C Convertible Preferred Stock | −44,873 | 0 | ||
| 2015-04-21 | Mickle Travis C President & CEO | Conversion · Series D Convertible Preferred Stock | −137,541 | 0 | ||
| 2015-04-21 | Mickle Travis C President & CEO | Conversion · Warrant to Purchase Series D Preferred Stock (right to buy) | −32,371 | $0.78 | $25K | 0 |
| 2015-04-21 | Mickle Travis C President & CEO | Conversion · Warrant to Purchase Common Stock (right to buy) | −4,316 | 4,316 | ||
| 2015-04-21 | Guenther Sven Exec VP R&D | Conversion | +23,852 | 43,852 | ||
| 2015-04-21 | Guenther Sven Exec VP R&D | Conversion · Series A Convertible Preferred Stock | −26,355 | 0 | ||
| 2015-04-21 | Guenther Sven Exec VP R&D | Conversion · Series B Convertible Preferred Stock | −16,129 | 0 | ||
| 2015-04-21 | Guenther Sven Exec VP R&D | Conversion · Series C Convertible Preferred Stock | −136,410 | 0 | ||
| 2015-04-15 | Clifton R. LaDuane VP Fin & Corp Controller | Grant or award · Stock Option (right to buy) | +21,333 | 21,333 |
Page 25 of 25 · 499 trades